Moderna seeks FDA approval of its new shot, mFlusvia, as option for 50 and older
US health advisers are debating a new kind of flu vaccine Thursday, the first made with the same mRNA technology that was key to ending the Covid-19 pandemic.
Moderna is seeking Food and Drug Administration (FDA) approval of its new shot , dubbed mFlusiva, as an option for people 50 and older. The FDA advisory committee meeting is a step toward a final decision ahead of the winter flu season.
Continue reading...
TH
Source
This article was originally published by The Guardian and written by Associated Press.
Read original article on The Guardian